With Royalty Stream Purchase, Cowen Is Bullish On Cetrotide In Fertility Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Aeterna Zentaris, facing cash-burn woes, sells off royalties for funding to advance top two pipeline candidates.
You may also be interested in...
NeurogesX Gets $40 Million To Fund U.S. Launch Of Qutenza Through Royalty Deal
Cowen Healthcare Royalty Partners provides the $40 million in exchange for royalties and sales milestones from areas controlled by Astellas.
NeurogesX Gets $40 Million To Fund U.S. Launch Of Qutenza Through Royalty Deal
Cowen Healthcare Royalty Partners provides the $40 million in exchange for royalties and sales milestones from areas controlled by Astellas.
Deals Of The Week: Pfizer Leads The Action Even After Wyeth Purchase
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.